Does the media prefer VKTX or MDGL?

In the previous week, Madrigal Pharmaceuticals had 5 more articles in the media than Viking Therapeutics. MarketBeat recorded 8 mentions for Madrigal Pharmaceuticals and 3 mentions for Viking Therapeutics. Madrigal Pharmaceuticals' average media sentiment score of 1.50 beat Viking Therapeutics' score of 0.50 indicating that Madrigal Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Viking Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Madrigal Pharmaceuticals 7 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor VKTX or LLY?

In the previous week, Eli Lilly and Company had 158 more articles in the media than Viking Therapeutics. MarketBeat recorded 161 mentions for Eli Lilly and Company and 3 mentions for Viking Therapeutics. Eli Lilly and Company's average media sentiment score of 1.06 beat Viking Therapeutics' score of 0.50 indicating that Eli Lilly and Company is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Viking Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Eli Lilly and Company 105 Very Positive mention(s) 20 Positive mention(s) 22 Neutral mention(s) 5 Negative mention(s) 9 Very Negative mention(s) Positive

Does the media prefer PFE or VKTX?

In the previous week, Pfizer had 67 more articles in the media than Viking Therapeutics. MarketBeat recorded 70 mentions for Pfizer and 3 mentions for Viking Therapeutics. Pfizer's average media sentiment score of 1.05 beat Viking Therapeutics' score of 0.50 indicating that Pfizer is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pfizer 46 Very Positive mention(s) 12 Positive mention(s) 7 Neutral mention(s) 3 Negative mention(s) 2 Very Negative mention(s) Positive Viking Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ASND or VKTX?

In the previous week, Ascendis Pharma A/S had 9 more articles in the media than Viking Therapeutics. MarketBeat recorded 12 mentions for Ascendis Pharma A/S and 3 mentions for Viking Therapeutics. Ascendis Pharma A/S's average media sentiment score of 1.42 beat Viking Therapeutics' score of 0.50 indicating that Ascendis Pharma A/S is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ascendis Pharma A/S 9 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Viking Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to VKTX or BBIO?

In the previous week, BridgeBio Pharma had 15 more articles in the media than Viking Therapeutics. MarketBeat recorded 18 mentions for BridgeBio Pharma and 3 mentions for Viking Therapeutics. BridgeBio Pharma's average media sentiment score of 1.04 beat Viking Therapeutics' score of 0.50 indicating that BridgeBio Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Viking Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BridgeBio Pharma 12 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Viking Therapeutics (VKTX) Competitors

$30.38 0.00 (0.00%)

Closing price 06/18/2026 04:00 PM Eastern

Extended Trading

$30.35 -0.03 (-0.10%)

As of 06/18/2026 07:53 PM Eastern

Compare

VKTX vs. MDGL, LLY, PFE, ASND, and BBIO

Should you buy Viking Therapeutics stock or one of its competitors? MarketBeat compares Viking Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Viking Therapeutics include Madrigal Pharmaceuticals (MDGL), Eli Lilly and Company (LLY), Pfizer (PFE), Ascendis Pharma A/S (ASND), and BridgeBio Pharma (BBIO). These companies are all part of the "medical" sector.

How does Viking Therapeutics compare to Madrigal Pharmaceuticals?

Viking Therapeutics (NASDAQ:VKTX) and Madrigal Pharmaceuticals (NASDAQ:MDGL) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, analyst recommendations, institutional ownership, valuation, media sentiment, risk and profitability.

Viking Therapeutics has a net margin of 0.00% compared to Madrigal Pharmaceuticals' net margin of -27.32%. Madrigal Pharmaceuticals' return on equity of -50.15% beat Viking Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Viking Therapeutics	N/A	-71.31%	-65.35%
Madrigal Pharmaceuticals	-27.32%	-50.15%	-25.44%

In the previous week, Madrigal Pharmaceuticals had 5 more articles in the media than Viking Therapeutics. MarketBeat recorded 8 mentions for Madrigal Pharmaceuticals and 3 mentions for Viking Therapeutics. Madrigal Pharmaceuticals' average media sentiment score of 1.50 beat Viking Therapeutics' score of 0.50 indicating that Madrigal Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Viking Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Madrigal Pharmaceuticals	7 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

76.0% of Viking Therapeutics shares are owned by institutional investors. Comparatively, 98.5% of Madrigal Pharmaceuticals shares are owned by institutional investors. 5.3% of Viking Therapeutics shares are owned by company insiders. Comparatively, 17.6% of Madrigal Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Viking Therapeutics currently has a consensus price target of $93.60, indicating a potential upside of 208.10%. Madrigal Pharmaceuticals has a consensus price target of $687.93, indicating a potential upside of 36.02%. Given Viking Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Viking Therapeutics is more favorable than Madrigal Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viking Therapeutics	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.79
Madrigal Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.78

Viking Therapeutics has a beta of 0.69, suggesting that its share price is 31% less volatile than the broader market. Comparatively, Madrigal Pharmaceuticals has a beta of -1.07, suggesting that its share price is 207% less volatile than the broader market.

Madrigal Pharmaceuticals has higher revenue and earnings than Viking Therapeutics. Madrigal Pharmaceuticals is trading at a lower price-to-earnings ratio than Viking Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viking Therapeutics	N/A	N/A	-$359.64M	-$4.14	N/A
Madrigal Pharmaceuticals	$958.40M	12.17	-$288.28M	-$12.80	N/A

Summary

Madrigal Pharmaceuticals beats Viking Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Viking Therapeutics compare to Eli Lilly and Company?

Viking Therapeutics (NASDAQ:VKTX) and Eli Lilly and Company (NYSE:LLY) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, earnings, valuation, profitability, dividends, media sentiment and institutional ownership.

Eli Lilly and Company has higher revenue and earnings than Viking Therapeutics. Viking Therapeutics is trading at a lower price-to-earnings ratio than Eli Lilly and Company, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viking Therapeutics	N/A	N/A	-$359.64M	-$4.14	N/A
Eli Lilly and Company	$65.18B	15.88	$20.64B	$28.15	39.03

Viking Therapeutics currently has a consensus target price of $93.60, indicating a potential upside of 208.10%. Eli Lilly and Company has a consensus target price of $1,227.74, indicating a potential upside of 11.74%. Given Viking Therapeutics' higher possible upside, equities research analysts clearly believe Viking Therapeutics is more favorable than Eli Lilly and Company.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viking Therapeutics	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.79
Eli Lilly and Company	1 Sell rating(s)	4 Hold rating(s)	23 Buy rating(s)	2 Strong Buy rating(s)	2.87

Eli Lilly and Company has a net margin of 34.98% compared to Viking Therapeutics' net margin of 0.00%. Eli Lilly and Company's return on equity of 105.77% beat Viking Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Viking Therapeutics	N/A	-71.31%	-65.35%
Eli Lilly and Company	34.98%	105.77%	23.76%

76.0% of Viking Therapeutics shares are owned by institutional investors. Comparatively, 82.5% of Eli Lilly and Company shares are owned by institutional investors. 5.3% of Viking Therapeutics shares are owned by company insiders. Comparatively, 0.1% of Eli Lilly and Company shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Eli Lilly and Company had 158 more articles in the media than Viking Therapeutics. MarketBeat recorded 161 mentions for Eli Lilly and Company and 3 mentions for Viking Therapeutics. Eli Lilly and Company's average media sentiment score of 1.06 beat Viking Therapeutics' score of 0.50 indicating that Eli Lilly and Company is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Viking Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Eli Lilly and Company	105 Very Positive mention(s)	20 Positive mention(s)	22 Neutral mention(s)	5 Negative mention(s)	9 Very Negative mention(s)	Positive

Viking Therapeutics has a beta of 0.69, indicating that its share price is 31% less volatile than the broader market. Comparatively, Eli Lilly and Company has a beta of 0.53, indicating that its share price is 47% less volatile than the broader market.

Summary

Eli Lilly and Company beats Viking Therapeutics on 12 of the 15 factors compared between the two stocks.

How does Viking Therapeutics compare to Pfizer?

Pfizer (NYSE:PFE) and Viking Therapeutics (NASDAQ:VKTX) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, profitability, earnings, media sentiment, risk, analyst recommendations, institutional ownership and dividends.

68.4% of Pfizer shares are held by institutional investors. Comparatively, 76.0% of Viking Therapeutics shares are held by institutional investors. 0.6% of Pfizer shares are held by insiders. Comparatively, 5.3% of Viking Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Pfizer has a net margin of 11.83% compared to Viking Therapeutics' net margin of 0.00%. Pfizer's return on equity of 19.44% beat Viking Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pfizer	11.83%	19.44%	8.41%
Viking Therapeutics	N/A	-71.31%	-65.35%

In the previous week, Pfizer had 67 more articles in the media than Viking Therapeutics. MarketBeat recorded 70 mentions for Pfizer and 3 mentions for Viking Therapeutics. Pfizer's average media sentiment score of 1.05 beat Viking Therapeutics' score of 0.50 indicating that Pfizer is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pfizer	46 Very Positive mention(s)	12 Positive mention(s)	7 Neutral mention(s)	3 Negative mention(s)	2 Very Negative mention(s)	Positive
Viking Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Pfizer has higher revenue and earnings than Viking Therapeutics. Viking Therapeutics is trading at a lower price-to-earnings ratio than Pfizer, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pfizer	$62.58B	2.30	$7.77B	$1.31	19.28
Viking Therapeutics	N/A	N/A	-$359.64M	-$4.14	N/A

Pfizer has a beta of 0.34, meaning that its stock price is 66% less volatile than the broader market. Comparatively, Viking Therapeutics has a beta of 0.69, meaning that its stock price is 31% less volatile than the broader market.

Pfizer currently has a consensus price target of $28.82, suggesting a potential upside of 14.13%. Viking Therapeutics has a consensus price target of $93.60, suggesting a potential upside of 208.10%. Given Viking Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Viking Therapeutics is more favorable than Pfizer.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pfizer	2 Sell rating(s)	12 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.25
Viking Therapeutics	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.79

Summary

Pfizer beats Viking Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Viking Therapeutics compare to Ascendis Pharma A/S?

Ascendis Pharma A/S (NASDAQ:ASND) and Viking Therapeutics (NASDAQ:VKTX) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, valuation, profitability, dividends, analyst recommendations, earnings, institutional ownership and risk.

Ascendis Pharma A/S has a beta of 0.39, indicating that its stock price is 61% less volatile than the broader market. Comparatively, Viking Therapeutics has a beta of 0.69, indicating that its stock price is 31% less volatile than the broader market.

Ascendis Pharma A/S presently has a consensus price target of $295.39, suggesting a potential upside of 27.97%. Viking Therapeutics has a consensus price target of $93.60, suggesting a potential upside of 208.10%. Given Viking Therapeutics' higher probable upside, analysts plainly believe Viking Therapeutics is more favorable than Ascendis Pharma A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ascendis Pharma A/S	1 Sell rating(s)	0 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	3.00
Viking Therapeutics	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.79

Ascendis Pharma A/S has higher revenue and earnings than Viking Therapeutics. Viking Therapeutics is trading at a lower price-to-earnings ratio than Ascendis Pharma A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ascendis Pharma A/S	$814.57M	17.68	-$258M	$8.67	26.62
Viking Therapeutics	N/A	N/A	-$359.64M	-$4.14	N/A

76.0% of Viking Therapeutics shares are owned by institutional investors. 40.0% of Ascendis Pharma A/S shares are owned by insiders. Comparatively, 5.3% of Viking Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Ascendis Pharma A/S had 9 more articles in the media than Viking Therapeutics. MarketBeat recorded 12 mentions for Ascendis Pharma A/S and 3 mentions for Viking Therapeutics. Ascendis Pharma A/S's average media sentiment score of 1.42 beat Viking Therapeutics' score of 0.50 indicating that Ascendis Pharma A/S is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ascendis Pharma A/S	9 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Viking Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Ascendis Pharma A/S has a net margin of 57.87% compared to Viking Therapeutics' net margin of 0.00%. Ascendis Pharma A/S's return on equity of 0.00% beat Viking Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ascendis Pharma A/S	57.87%	N/A	-8.37%
Viking Therapeutics	N/A	-71.31%	-65.35%

Summary

Ascendis Pharma A/S beats Viking Therapeutics on 12 of the 15 factors compared between the two stocks.

How does Viking Therapeutics compare to BridgeBio Pharma?

Viking Therapeutics (NASDAQ:VKTX) and BridgeBio Pharma (NASDAQ:BBIO) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, risk, valuation, analyst recommendations, media sentiment, dividends and earnings.

In the previous week, BridgeBio Pharma had 15 more articles in the media than Viking Therapeutics. MarketBeat recorded 18 mentions for BridgeBio Pharma and 3 mentions for Viking Therapeutics. BridgeBio Pharma's average media sentiment score of 1.04 beat Viking Therapeutics' score of 0.50 indicating that BridgeBio Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Viking Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BridgeBio Pharma	12 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Viking Therapeutics has a net margin of 0.00% compared to BridgeBio Pharma's net margin of -124.42%. BridgeBio Pharma's return on equity of 0.00% beat Viking Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Viking Therapeutics	N/A	-71.31%	-65.35%
BridgeBio Pharma	-124.42%	N/A	-65.81%

Viking Therapeutics has higher earnings, but lower revenue than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than Viking Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viking Therapeutics	N/A	N/A	-$359.64M	-$4.14	N/A
BridgeBio Pharma	$502.08M	25.85	-$724.93M	-$3.74	N/A

Viking Therapeutics currently has a consensus target price of $93.60, suggesting a potential upside of 208.10%. BridgeBio Pharma has a consensus target price of $91.05, suggesting a potential upside of 37.39%. Given Viking Therapeutics' higher possible upside, equities analysts plainly believe Viking Therapeutics is more favorable than BridgeBio Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viking Therapeutics	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.79
BridgeBio Pharma	1 Sell rating(s)	2 Hold rating(s)	22 Buy rating(s)	0 Strong Buy rating(s)	2.84

76.0% of Viking Therapeutics shares are held by institutional investors. Comparatively, 99.9% of BridgeBio Pharma shares are held by institutional investors. 5.3% of Viking Therapeutics shares are held by insiders. Comparatively, 14.2% of BridgeBio Pharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Viking Therapeutics has a beta of 0.69, meaning that its stock price is 31% less volatile than the broader market. Comparatively, BridgeBio Pharma has a beta of 0.97, meaning that its stock price is 3% less volatile than the broader market.

Summary

BridgeBio Pharma beats Viking Therapeutics on 10 of the 16 factors compared between the two stocks.

Get Viking Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VKTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VKTX vs. The Competition

Export

Metric	Viking Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$3.53B	$3.41B	$6.43B	$12.60B
Dividend Yield	N/A	2.32%	2.68%	5.81%
P/E Ratio	-7.34	19.73	24.75	24.42
Price / Sales	N/A	320.10	530.01	109.07
Price / Cash	N/A	127.84	45.07	55.09
Price / Book	5.38	8.16	10.80	6.58
Net Income	-$359.64M	$23.94M	$3.57B	$337.17M
7 Day Performance	5.67%	2.57%	0.73%	0.83%
1 Month Performance	3.19%	2.35%	1.35%	3.27%
1 Year Performance	16.80%	55.09%	29.31%	36.05%

Viking Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VKTX Viking Therapeutics	2.5811 of 5 stars	$30.38 flat	$93.60 +208.1%	+15.6%	$3.53B	N/A	N/A	20
MDGL Madrigal Pharmaceuticals	3.7486 of 5 stars	$471.32 -1.2%	$687.00 +45.8%	+78.9%	$11.00B	$1.13B	N/A	90	Positive News
LLY Eli Lilly and Company	4.4324 of 5 stars	$1,138.78 -0.5%	$1,227.74 +7.8%	+40.1%	$1.08T	$65.18B	40.45	50,000	Trending News
PFE Pfizer	4.0923 of 5 stars	$25.61 -0.4%	$28.82 +12.6%	+5.8%	$146.48B	$62.58B	19.55	75,000	Trending News
ASND Ascendis Pharma A/S	4.9072 of 5 stars	$209.79 -1.6%	$295.39 +40.8%	+35.2%	$13.30B	$865.78M	24.20	1,189	News Coverage Positive News Analyst Downgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VKTX) was last updated on 6/20/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Viking Therapeutics (VKTX) Competitors

VKTX vs. MDGL, LLY, PFE, ASND, and BBIO

How does Viking Therapeutics compare to Madrigal Pharmaceuticals?

Summary

How does Viking Therapeutics compare to Eli Lilly and Company?

Summary

How does Viking Therapeutics compare to Pfizer?

Summary

How does Viking Therapeutics compare to Ascendis Pharma A/S?

Summary

How does Viking Therapeutics compare to BridgeBio Pharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VKTX vs. The Competition

Viking Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Viking Therapeutics (VKTX) Competitors

VKTX vs. MDGL, LLY, PFE, ASND, and BBIO

How does Viking Therapeutics compare to Madrigal Pharmaceuticals?

Is VKTX or MDGL more profitable?

Does the media prefer VKTX or MDGL?

Do institutionals & insiders believe in VKTX or MDGL?

Do analysts recommend VKTX or MDGL?

Which has more risk and volatility, VKTX or MDGL?

Which has higher earnings and valuation, VKTX or MDGL?

Summary

How does Viking Therapeutics compare to Eli Lilly and Company?

Which has higher valuation and earnings, VKTX or LLY?

Do analysts prefer VKTX or LLY?

Is VKTX or LLY more profitable?

Do institutionals and insiders believe in VKTX or LLY?

Does the media favor VKTX or LLY?

Which has more risk & volatility, VKTX or LLY?

Summary

How does Viking Therapeutics compare to Pfizer?

Do institutionals & insiders hold more shares of PFE or VKTX?

Is PFE or VKTX more profitable?

Does the media prefer PFE or VKTX?

Which has better valuation and earnings, PFE or VKTX?

Which has more risk and volatility, PFE or VKTX?

Do analysts prefer PFE or VKTX?

Summary

How does Viking Therapeutics compare to Ascendis Pharma A/S?

Which has more volatility and risk, ASND or VKTX?

Do analysts recommend ASND or VKTX?

Which has higher valuation and earnings, ASND or VKTX?

Do insiders and institutionals hold more shares of ASND or VKTX?

Does the media prefer ASND or VKTX?

Is ASND or VKTX more profitable?

Summary

How does Viking Therapeutics compare to BridgeBio Pharma?

Does the media refer more to VKTX or BBIO?

Is VKTX or BBIO more profitable?

Which has preferable valuation & earnings, VKTX or BBIO?

Do analysts recommend VKTX or BBIO?

Do insiders and institutionals have more ownership in VKTX or BBIO?

Which has more risk and volatility, VKTX or BBIO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VKTX vs. The Competition

Viking Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools